A T>G single nucleotide polymorphism (SNP, rs2279744) of the MDM2 gene has been investigated in sarcoma community, but the findings are conflicting. This study was designed to well define the relationship between SNP rs2279744 and sarcoma risk. We did a systematic computerized search of the PubMed, Web of Science, and Science Direct databases to identify the human case–control studies investigating the relationship between SNP rs2279744 and sarcoma risk with complete genetic data. Pooled odds ratios (ORs) were calculated with the Mantel–Haenszel fixed-effect model or the DerSimonian and Laird random effects model to estimate the risk of sarcoma. Overall analysis included five independent studies. On the whole, the T/G genotype or the combined G/G and T/G genotypes appeared to be associated with approximately 1.40-fold higher risk of sarcoma relative to the T/T genotype (T/G vs. T/T: OR 1.33, 95 % CI 1.00–1.77; G/G + T/G vs. T/T: OR 1.42, 95 % CI 1.08–1.85). We noted that the Caucasian populations showed a similarly increased risk of sarcoma ascribed to the carriage of the same genotypes (T/G vs. T/T: OR 1.41, 95 % CI 1.05–1.90; G/G + T/G vs. T/T: OR 1.49, 95 % CI 1.13–1.97). This meta-analysis provides evidence that MDM2 SNP rs2279744 may be significantly associated with increased risk of sarcoma in Caucasian individuals.
MDM2Sarcoma SNP Risk
This is a preview of subscription content, log in to check access.
Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein–thirty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 1999;59(1):1–7.PubMedGoogle Scholar
Bond GL et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591–602.CrossRefPubMedGoogle Scholar
Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005;65(13):5481–4.CrossRefPubMedGoogle Scholar
Thurow HS et al. Ewing sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs. Mol Biol Rep. 2013;40(8):4929–34.CrossRefPubMedGoogle Scholar
Tornesello ML et al. MDM2 and CDKN1A gene polymorphisms and risk of Kaposi’s sarcoma in African and Caucasian patients. Biomarkers. 2011;16(1):42–50.CrossRefPubMedGoogle Scholar
Toffoli G et al. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res. 2009;15(10):3550–6.CrossRefPubMedGoogle Scholar
Alhopuro P et al. The MDM2 promoter polymorphism SNP309T–>G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet. 2005;42(9):694–8.CrossRefPubMedPubMedCentralGoogle Scholar
Oliner JD et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358(6381):80–3.CrossRefPubMedGoogle Scholar
Cordon-Cardo C et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994;54(3):794–9.PubMedGoogle Scholar
Birgander R et al. The codon 31 polymorphism of the p53-inducible gene p21 shows distinct differences between major ethnic groups. Hum Hered. 1996;46(3):148–54.CrossRefPubMedGoogle Scholar
Arva NC et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem. 2005;280(29):26776–87.CrossRefPubMedGoogle Scholar
Ruijs MW et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet. 2007;15(1):110–4.CrossRefPubMedGoogle Scholar
Cai X, Yang M. The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis. J Cancer Res Clin Oncol. 2012;138(4):555–61.CrossRefPubMedGoogle Scholar